LATEST NEWS & PUBLICATIONS
Understanding Prescription Drug Line Extensions: Key Insights on URA, Medicaid Rebates, and 340B Program Impact
For pharmaceutical manufacturers acquiring or launching brand drugs, line extensions remain a topic fraught with frequent inquiries and complexities. Line extensions, with their unique formulas to determine the Unit Rebate Amount (URA), can often be a source of...
Navigating Change: A Deep Dive into the Pending CMS Rule (CMS-2434) for Pharma Manufacturers
Navigating Change: A Deep Dive into the Pending CMS Rule (CMS-2434) for Pharma Manufacturers The CMS Final Rule currently pending holds significant implications for pharmaceutical manufacturers. Within the Office of Information and Regulatory Affairs (OIRA), there are...
Navigating the Texas Medicaid Formulary: A Comprehensive Guide for Pharmaceutical Manufacturers
NAVIGATING THE TEXAS MEDICAID FORMULARY: A Comprehensive Guide for Pharmaceutical ManufacturersThe landscape of pharmaceutical product listing in Texas presents unique challenges for manufacturers seeking Medicaid coverage. Unlike other states, Texas operates its own...
OUR DIFFERENCE
Access
- Direct access to your analyst and company leadership
- Available 24/7 to support your needs
Accuracy
- Apply discipline to fully compliant SOPs
- All deliverables subject to strict layers of reviews and audits
Dependability
- Consistent ownership & business partners
- Vested in your long-term success
Transparency
- Clients own all data
- Full access to all scrubbed data, computations and processes
Problems Solved — Opportunities Leveraged.
Find out how we can support your critical analytic, processing and financial functions.